ArkBio Announces the Completion of Phase III Clinical Study for AK0901 in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in China SHANGHAI, March 24, 2025 /PRNewswire/ — Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")… CISION PRNewswireMarch 24, 2025
Evolve: The Latest GPU Benchmark Suite Revolutionary tool redefines performance evaluation for the graphics industry BREDA, Netherlands, March… CISION PRNewswireMarch 24, 2025
Press ReleaseRegistration is On! 2025 CWIEME Shanghai – Your Gateway to Innovation & Connections SHANGHAI, March 24, 2025 /PRNewswire/ — 2025 CWIEME Shanghai is proud to… CISION PRNewswireMarch 24, 2025
CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer SUZHOU, China, March 24, 2025 /PRNewswire/ — CStone Pharmaceuticals ("CStone", HKEX: 2616),… CISION PRNewswireMarch 24, 2025
Strider Named to Fast Company's 2025 List of Most Innovative Companies Strategic intelligence firm ranked in the top ten for most innovative security company… CISION PRNewswireMarch 24, 2025
Asia's First Single Stock Leveraged & Inverse Products to Debut on HKEX HONG KONG, March 24, 2025 /PRNewswire/ — CSOP Asset Management Limited (CSOP),… CISION PRNewswireMarch 24, 2025
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer SAN FRANCISCO and SUZHOU, China, March 24, 2025 /PRNewswire/ — Innovent Biologics, Inc.… CISION PRNewswireMarch 24, 2025
AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development Accelerates HONG KONG, March 24, 2025 /PRNewswire/ — AIM Vaccine Co., Ltd. (06660.HK),… CISION PRNewswireMarch 24, 2025
